Drugs / Pivanex
Pivanex
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00087477 | Jan → Aug 2004 | melanoma | Titan Pharmaceuticals | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00083473 | May 2004 → Apr 2005 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Titan Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00073385 | Sep 2003 → Oct 2004 | non-small cell lung carcinoma | Titan Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pivanex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00087477 ↗ |
| Known as | Butyric acid 2,2-dimethyl-propionyloxymethyl ester | ChEMBL registry synonym — accepted as the source's own label CHEMBL100014 ↗ |
| Known as | Butyric acid 2,2-dimethyl-propionyloxymethyl ester(an9) | ChEMBL registry synonym — accepted as the source's own label CHEMBL100014 ↗ |
| Known as | pivaloyloxymethyl butyrate | “Pivanex (pivaloyloxymethyl butyrate) is an HDAC inhibitor” NCT00083473 ↗ |
| Action | Inhibit | “Pivanex is a histone deacetylase inhibitor” NCT00073385 ↗ |
| Modality | Small molecule | — CHEMBL100014 ↗ |
| Route | Intravenous | “Patients receive the combination of Pivanex intravenously on Days 1-3” NCT00073385 ↗ |